Phase 3
Completed N=26
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Source: ClinicalTrials.gov NCT02334813 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Remission Duration — 3; 11 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6 mg/kg/d, days 1-4; arm B). The primary endpoint is duration of remission defined as platelets ≥50/nl.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Remission Duration |
3; 11 | — |
Eligibility Criteria
Inclusion Criteria
- First episode of ITP
Exclusion Criteria
- Pregnancy
- Glucocorticoid intolerance
Data sourced from ClinicalTrials.gov (NCT02334813). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.